CollabNet Announces Agreement With Cardinal Health to Use TeamForge for Software Development

BRISBANE, Calif., April 9, 2013 -- CollabNet® (www.collab.net), the global leader for Enterprise Cloud Development, today announced that Cardinal Health, Inc. – one of the world's largest healthcare services companies – has selected its TeamForge ALM platform to support its enterprise software development initiatives around the globe. Cardinal Health selected TeamForge to replace its legacy platform. TeamForge provides the flexibility and integration capabilities Cardinal Health wants to adopt and use a wider range of both commercial and open source tools.

"Cost-effective cloud solutions for software development organizations with complex projects are now a baseline requirement for companies in healthcare and many other industries," said Bill Portelli, co-founder and CEO for CollabNet.  "TeamForge provides the detailed, traceable and documented accountability organizations like Cardinal Health need to better manage software development and remain nimble in the market."

More information about TeamForge is available at www.collab.net/products/teamforge

"Cardinal Health is committed to driving efficiencies in the healthcare supply chain, and developing quality software is essential to both our internal business operations and the services we deliver to customers," said Andy Hoover, director, enterprise information technology for Cardinal Health.  "CollabNet's TeamForge platform will enable our development teams to work more efficiently and collaboratively, both in the cloud and within the desktop IDE environment of choice, to create better software, faster."

Cardinal Health has more than 500 globally dispersed employees and contractors – including software developers, product and project managers, quality assurance engineers and development managers – who will use TeamForge through a hybrid deployment model. It selected TeamForge for its flexible, open and collaborative architecture that allows teams to work within on-premise and/or cloud-based environments quickly and within a consistent management infrastructure. TeamForge leads to lower cost of operations as it is able to scale to thousands of developers with very few additional resources. Its social and intuitive graphical user experience increase collaboration, code re-use and productivity across all development teams. 

From a technical standpoint, Cardinal Health liked TeamForge's integration features that will tightly integrate open source tools, including software configuration management and continuous integration tools, together with commercial offerings, like HP Quality Center. TeamForge also offers a sophisticated audit tracing and tracking functionality that supports existing business processes and procedures.

About CollabNet

CollabNet is a leading provider of Enterprise Cloud Development. With more than 10,000 global customers, the company provides a suite of platforms and services to address three major trends disrupting the software industry: Agile, DevOps and hybrid cloud development. Its CloudForge™ development-Platform-as-a-Service (dPaaS) enables cloud development through a flexible platform that is team friendly, enterprise ready and integrated to support leading third party tools. The CollabNet TeamForge® ALM, ScrumWorks® Pro Agile project management and Subversion Edge and Enterprise Git source code management platforms can be deployed separately or together, in the cloud or on-premise. CollabNet complements its technical offerings with industry leading consulting and training services for Agile and cloud development transformations. Many CollabNet customers improve productivity by as much as 70 percent, while reducing costs by 80 percent. For more information, please visit (www.collab.net).

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.